We are committed to serving the best interests of our shareholders.

Filter Releases
 
Press Releases
Date Title and Summary View
4/25/2013 Phase 3 Trial of Niraparib in Breast Cancer to be Initiated in the Second Half of 2013Phase 3 Trial of Niraparib in Ovarian Cancer on Track to Begin Enrolling Mid-2013Top-Line Results of Rolapitant Phase 3 Program to be Announced in the Second Half of 2013Fifth Dose Level Achieved in Phase 1/2 Clinical Trial of TSR-011Net Cash Position Totaled Appr...
4/17/2013 WALTHAM, Mass., April 17, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its first quarter 2013 financial results on Thursday, April 25, 2013, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday, April 25, 2013 at 4:30 p.m. ET to discuss the Comp...
3/28/2013 WALTHAM, Mass., March 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the 20th Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel and Conference Center in New York City on Friday, April 5, 2013 at 1:3...
3/05/2013 WALTHAM, Mass., March 5, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today the closing of its previously announced underwritten public offering of common stock. The total number of shares of common stock sold was 5,428,000, composed of 4,720,000 shares of common stock initially offered and an additional 708,000 shares of common st...
2/28/2013 WALTHAM, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 4,720,000 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds from the offering will be approximately $85 million upsized from the previously annou...
2/25/2013 WALTHAM, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has commenced an underwritten public offering of $75 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional $11,250,000 shares of its common stock to cover over...
2/14/2013 Niraparib to be Advanced in a Phase 3 Pivotal Trial for Ovarian CancerEnrollment Continues in the Global Registration Program for RolapitantAchieved Third Dose-level in a Phase 1/2 Clinical Trial of TSR-011 WALTHAM, Mass., Feb. 14, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) an oncology-focused biopharmaceutical company today reported f...
2/11/2013 WALTHAM, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its fourth quarter and year end 2012 financial results on Thursday, February 14th, 2013, before the opening of the U.S. financial markets. TESARO's senior management will host a conference call and live webcast on Thursday, February 14th, 2013, at 8:00 a.m. E...
2/06/2013 WALTHAM, Mass., Feb. 6, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the Leerink Swann Global Healthcare Conferenceat the Waldorf Astoria Hotel in New York on Thursday, February 14, 2013 at 11:00...
11/29/2012 WALTHAM, Mass., Nov. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the Deutsche Bank 2012 dbAccess BioFEST at the Four Seasons Hotel in Boston on Monday, December 3, 2012 at 3:25 p.m. EDT. ...
= add release to Briefcase